COMPASS三维验证系统在食管癌容积旋转调强放疗中的应用

王晓敏; 唐广; 顾浩; 赵一电; 王海洋; 樊锐太

doi:10.3971/j.issn.1000-8578.2018.18.0431

COMPASS三维验证系统在食管癌容积旋转调强放疗中的应用

Application of COMPASS 3D Dose Validation System in Volumetric Modulated Arc Therapy of Esophageal Cancer

摘要

摘要:
目的探讨COMPASS三维验证系统在食管癌容积旋转调强剂量验证中的可行性。
方法选取37例食管癌初治患者在Oncentra计划系统上进行容积旋转调强(VMAT)计划设计, 然后将治疗计划传送至COMPASS验证系统和加速器上。比较计划系统中的计算结果和COMPASS验证系统中实际测量结果之间的差异。分析靶区的平均剂量(Dmean)、95%体积受照射的剂量(D95)和γ值, 危及器官比较双肺V20、V30剂量值。
结果计算结果和测量结果在靶区上的γ通过率均 > 92%, 靶区D95的平均值偏差 < 3%, Dmean标准偏差平均值< 1%。测量结果与计划结果中双肺V20、V30分别为(19.86±2.18)%、(20.03±2.21)%和(12.35±2.61)%、12.40±2.52)%, 明显看出测量的结果V20、V30比计算结果小。
结论 COMPASS三维验证系统能准确快速的分析出结果, 保证食管癌治疗的安全。

Abstract:
Objective To explore the feasibility of COMPASS 3D dose verification system in volumetric modulated arc therapy of esophageal cancer.
Methods We selected 37 patients newly diagnosed as esophageal neoplasm to make VMAT design based on the Oncentra planning system, and then transferred the treatment plan to the COMPASS validation system and the accelerator.We compared the calculated results in the planned system with the actual measurements in the COMPASS validation system.We obtained the Gamma passing rate, separately D95 and Dmean of the gross tumor volume(GTV) and the planning target volume(PTV), and compared the V20 and V30 dose values of the total lung.
Results The calculated results and the measured results of the γ pass rate were higher than 92% respectively.The average dose difference for D95 was less than 3% for most treatment plans and the average difference for the target volumes(Dmean) was less than 1%.The average difference for V20 and V30 of the total lung were (9.86±2.18, 20.03±2.21)% and (12.35±2.61, 12.40±2.52)% in the calculated results and the measured results, respectively.
Conclusion COMPASS 3D validation system could analyze the results accurately and quickly, ensure the safety of esophageal cancer treatment.

HTML全文

参考文献(20)

施引文献

资源附件(0)